CXCL8 and neoplasm: Although, to our knowledge, there are no clinical trial results for this antibody in metastatic melanoma, ABX-IL8 did show promising results in pre-clinical melanoma studies, reducing tumor growth and angiogenesis in A375SM and TXM-13 xenografts in nude mice [136].